| Registry | NCT03606707 |
|---|---|
| Status | Unknown |
| Phase | Early Phase 1 |
| Study type | Interventional; randomized, parallel, masking: double, treatment |
| Enrollment | 60 (Estimated) |
| Sponsor | Assiut University (Other) |
| Conditions | Pain, Head, Sleep Disturbance |
| Interventions | Steroids (Drug) |
| Dates | start 2018-06-01, primary completion 2018-07-15, completion 2018-08-01 (estimated), first posted 2018-07-31, last updated 2018-07-31 |
| Locations | 2 sites in Egypt |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Pain, Head All trials for Sleep Disturbance All trials of Steroids
Efficacy of intra-articular steroid injection for inflamed atlantoaxial joint in patients with rheumatoid arthritis Inclusion criteria Patients with rheumatoid arthritis with MRI findings of atlantoaxial joint inflammation and failure of resolution after 2 weeks systemic steroid administration Exclusion criteria Coagulopathy, allergy to contrast material, pregnancy Interventional group (AS) group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day.
Efficacy of intra-articular steroid injection for inflamed atlantoaxial joint on sleep quality and head and neck pain in patients with rheumatoid arthritis Inclusion criteria Patients with rheumatoid arthritis with MRI findings of atlantoaxial joint inflammation and failure of resolution after 2 weeks systemic steroid administration Interventional group (AS) group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| corticosteroid | Experimental | Drug: Steroids | steroid group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day. |
| oral steroid | No intervention | systemic group, received systemic steroid 20 mg/d , in addition to methotrexate and chloroquine 400 mg per day. |
Sex: All, ages: 20 Years to 80 Years
Inclusion Criteria: * Patients with rheumatoid arthritis with MRI findings of atlantoaxial joint inflammation and failure of resolution after 2 weeks systemic steroid administration Exclusion Criteria: * Coagulopathy, allergy to contrast material, pregnancy
| Facility | City | Country | Status |
|---|---|---|---|
| Manal Hassanien | Asyut, Assuit | Egypt | Recruiting |
| Assiut governorate | Asyut | Egypt | Recruiting |